Martha Marsh - Edwards Lifesciences Lead Independent Director

EW Stock  USD 95.56  0.41  0.43%   

Director

Ms. Martha H. Marsh is Independent Director of the Edwards Lifesciences Corporationration Ms. Marshs experience of more than 30 years in an increasingly complex and evolving healthcare system as a president and chief executive officer, combined with years of board experience that includes corporate governance chairmanships, provide a unique perspective as our Board considers the execution of our patientfocused innovation strategy. since 2020.
Age 72
Tenure 4 years
Address One Edwards Way, Irvine, CA, United States, 92614
Phone949 250 2500
Webhttps://www.edwards.com

Edwards Lifesciences Management Efficiency

The company has Return on Asset (ROA) of 0.1225 % which means that for every $100 of assets, it generated a profit of $0.1225. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.2234 %, which means that it produced $0.2234 on every 100 dollars invested by current stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to 0.14 in 2024. Return On Assets is likely to drop to 0.08 in 2024. At this time, Edwards Lifesciences' Fixed Asset Turnover is fairly stable compared to the past year. Asset Turnover is likely to climb to 0.80 in 2024, whereas Return On Assets are likely to drop 0.08 in 2024.
The company reports 694.9 M of total liabilities with total debt to equity ratio (D/E) of 0.11, which may suggest the company is not taking enough advantage from financial leverage. Edwards Lifesciences Corp has a current ratio of 3.75, indicating that it is in good position to pay out its debt commitments in time. Debt can assist Edwards Lifesciences until it has trouble settling it off, either with new capital or with free cash flow. So, Edwards Lifesciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Edwards Lifesciences Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Edwards to invest in growth at high rates of return. When we think about Edwards Lifesciences' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Frederick SotokGentex
83
Kam YuenVisteon Corp
69
Harrington BischofOld Republic International
85
Kirk HachigianPACCAR Inc
58
Kathleen StarkoffGentex
60
John DixonOld Republic International
81
Forest FarmerAmerican Axle Manufacturing
72
Chris SonAmerican Axle Manufacturing
N/A
Jason ParsonsAmerican Axle Manufacturing
N/A
Steven WalkerOld Republic International
75
Gary GoodeGentex
72
Samuel ValentiAmerican Axle Manufacturing
75
Dame CarnwathPACCAR Inc
65
John VollaroArch Capital Group
79
Leslie BrownGentex
64
John SmithAmerican Axle Manufacturing
70
Robert ManzoVisteon Corp
61
Eugene SunshineArch Capital Group
68
Naomi BergmanVisteon Corp
55
Kewsong LeeArch Capital Group
51
John BunceArch Capital Group
59
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. Edwards Lifesciences operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 15700 people. Edwards Lifesciences Corp (EW) is traded on New York Stock Exchange in USA. It is located in One Edwards Way, Irvine, CA, United States, 92614 and employs 19,800 people. Edwards Lifesciences is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Edwards Lifesciences Corp Leadership Team

Elected by the shareholders, the Edwards Lifesciences' board of directors comprises two types of representatives: Edwards Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edwards. The board's role is to monitor Edwards Lifesciences' management team and ensure that shareholders' interests are well served. Edwards Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edwards Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Paul LaViolette, Independent Director
John Cardis, Independent Director
Wesley Schack, Presiding Independent Director
Larry Wood, Corporate Vice President - Transcatheter Aortic Valve Replacement
Leslie Heisz, Independent Director
Catherine Szyman, Corporate Vice President - Critical Care
Arnold Pinkston, Corporate Counsel
Barbara McNeil, Independent Director
Steven Loranger, Independent Director
Scott Ullem, Chief Financial Officer, Corporate Vice President
Patrick Verguet, Corporate VP of EMEA, Canada and Latin America
Kieran Gallahue, Independent Director
Nicholas Valeriani, Independent Director
Heisz Stone, Independent Director
Mark Wilterding, Vice Relations
MD FACC, Corporate Officer
Martha Marsh, Lead Independent Director
Daveen Chopra, Corporate Vice President - Surgical Structural Heart
Huimin Wang, Corporate Vice President - Japan, Asia and Pacific
JeanLuc Lemercier, Corporate Vice President - EMEA (Europe, Middle East and Africa)
Christine McCauley, Corporate Resources
William Link, Independent Director
Ramona Sequeira, Independent Director
Bernard Zovighian, Corporate Vice President -Surgical Heart Valve Therapy
David Erickson, Vice President - Investor Relations
Donald Bobo, Corporate Vice President - Strategy and Corporate Development
Todd Brinton, Co Officer
Dirksen Lehman, Corporate Affairs
Michael Mussallem, Chairman of the Board, Chief Executive Officer

Edwards Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Edwards Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Edwards Lifesciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edwards Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edwards Lifesciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with Edwards Stock

  0.89BSX Boston Scientific Corp Financial Report 24th of April 2024 PairCorr
  0.68COO Cooper Companies Financial Report 6th of June 2024 PairCorr

Moving against Edwards Stock

  0.86MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.81PHG Koninklijke Philips Financial Report 22nd of April 2024 PairCorr
  0.73MBIO Mustang Bio Report 3rd of April 2024 PairCorr
  0.71PIIIW P3 Health PartnersPairCorr
  0.69TFX Teleflex Incorporated Financial Report 2nd of May 2024 PairCorr
The ability to find closely correlated positions to Edwards Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edwards Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edwards Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edwards Lifesciences Corp to buy it.
The correlation of Edwards Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edwards Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edwards Lifesciences Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edwards Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Edwards Lifesciences Corp is a strong investment it is important to analyze Edwards Lifesciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Edwards Lifesciences' future performance. For an informed investment choice regarding Edwards Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Edwards Stock analysis

When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Is Edwards Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edwards Lifesciences. If investors know Edwards will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edwards Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.06)
Earnings Share
2.31
Revenue Per Share
9.897
Quarterly Revenue Growth
0.138
Return On Assets
0.1225
The market value of Edwards Lifesciences Corp is measured differently than its book value, which is the value of Edwards that is recorded on the company's balance sheet. Investors also form their own opinion of Edwards Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Edwards Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edwards Lifesciences' market value can be influenced by many factors that don't directly affect Edwards Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edwards Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edwards Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edwards Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.